Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 15, 2009

Zymeworks and XOMA Collaborate on Antibody Optimization

  • Zymeworks entered into a research agreement with XOMA to optimize an antibody. The partnership will leverage Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s Targeted Affinity Enhancement™ technology.

    ZymeCAD molecular simulation platform creates a modeling environment that generates novel physical and chemical insights into protein systems, according to Zymeworks.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »